BioCentury | May 20, 2019
Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

...cell lymphoma (MCL); B cell lymphoma Patient sample, cell culture and mouse studies identified an OXPHOS complex I...
...associated with resistance to Imbruvica. In two Imbruvica-resistant human MCL cell lines, a tool compound OXPHOS complex I...
...testing for multiple other cancers. ImmunoMet Therapeutics Inc. has IM156, a biguanide derivative that inhibits OXPHOS complex I...
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Apr 30, 2019
Distillery Therapeutics

OXPHOS complex V inhibitor to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies identified a benzimidazolinium-based inhibitor of OXPHOS complex V that could help treat glioblastoma. Screening of 200,000 small molecules in primary mouse glioblastoma cells yielded...
BioCentury | Jan 16, 2019
Distillery Therapeutics

Cancer

...lung cancer Cell culture and mouse studies suggest inhibiting PGD alone or in combination with OXPHOS complex I...
...volume. In three human NSCLC cell lines, the PGD-targeting shRNA plus IACS-010759, an inhibitor of OXPHOS complex I...
...leukemia (AML) and solid tumors. ImmunoMet Therapeutics Inc. has IM156, a biguanide derivative that inhibits OXPHOS complex I...
BioCentury | Nov 3, 2017
Clinical News

ImmunoMet starts Phase I of IM156 for solid tumors

...Secondary endpoints include preliminary tumor response and pharmacokinetics. IM156 is a biguanide derivative that inhibits mitochondrial oxidative phosphorylation complex I (OXPHOS complex I)...
...Texas Product: IM156 (formerly HL156Can) Business: Cancer Molecular target: Mitochondrial oxidative phosphorylation complex I (OXPHOS complex I) Description: Biguanide derivative that inhibits OXPHOS complex I...
...response and pharmacokinetics Status: Phase I started Milestone: NA Elizabeth S. Eaton IM156 HanAll Biopharma Co. Ltd. ImmunoMet Therapeutics Inc. Mitochondrial oxidative phosphorylation complex I (OXPHOS complex I)...
BioCentury | Jun 16, 2017
Emerging Company Profile

Metabolic regulation

...biguanide metformin can inhibit this method of metabolism. The drug decreases ATP production by inhibiting mitochondrial oxidative phosphorylation complex I (OXPHOS complex I)...
...of over 1,000 biguanide derivatives for cancer. Lead compound IM156 is a preclinical inhibitor of OXPHOS complex I...
...in this program is IM188 . Cowen said IM188 is a much weaker inhibitor of OXPHOS complex I...
Items per page:
1 - 6 of 6